Drug recall · June 15, 2022
Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE recall
Why: Failed Impurities/Degradation Specifications.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Xiidra (lifitegrast ophthalmic solution) 5% PROFESSIONAL SAMPLE, packaged in a) 5 single-use containers (0.2 mL each vial) (NDC 0078-0911-95) and b) 4 pouches x 5 single-use containers (NDC 0078-0911-94), Rx Only, Manufactured by: The Ritedose Corporation Columbia, SC 29203; Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936.
- Lots / codes
Lot #: a) and b) 20DJ3, Exp. Date 03/2023.
- Quantity
- 279,179 vials
- Company
- Novartis Pharmaceuticals Corporation, East Hanover, NJ
- Distribution
- Nationwide within the United States
- Initiated
- May 10, 2022 · Voluntary: Firm initiated
- Classified
- June 6, 2022
- Reported
- June 15, 2022
- Ended
- February 28, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Xiidra
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.